ArticleExperimental and therapeutic medicine2026

A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry study.

Chun-Nan Yeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.